ArticleFrontiers in immunology2025
Case Report: A case of reversible pulmonary bullae induced by camrelizumab: a new immune-related adverse event.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the widespread clinical application of immune checkpoint inhibitors (ICIs), the treatment of lung squamous cell carcinoma (LUSC) has entered a new era, characterized by equal emphasis on precision medicine and immunotherapy. Among these, programmed cell death protein-1 (PD-1) inhibitors have demonstrated significant efficacy in prolonging patient survival. However, while immunotherapy provides substantial clinical benefits, it may also induce immune-related adverse events (irAEs). We report a case of a 74-year-old male with LUSC who developed reversible pulmonary bullae following camrelizumab treatment. The patient presented with a one-year history of cough. Chest CT revealed a right hilar mass (11×10cm) with pleural effusion. Histopathological analysis of EBUS-TBNA specimens confirmed squamous cell carcinoma. Comprehensive systemic evaluation established the diagnosis of right lung squamous cell carcinoma (cT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.